- Home
- CPTN vs SCYX Comparison
CPTN vs SCYX Comparison
Compare CPTN & SCYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CPTN
- SCYX
- Stock Information
- Founded
- CPTN 2016
- SCYX 1999
- Country
- CPTN United States
- SCYX United States
- Employees
- CPTN N/A
- SCYX N/A
- Industry
- CPTN Industrial Machinery/Components
- SCYX Biotechnology: Pharmaceutical Preparations
- Sector
- CPTN Industrials
- SCYX Health Care
- Exchange
- CPTN Nasdaq
- SCYX Nasdaq
- Market Cap
- CPTN 51.4M
- SCYX 50.3M
- IPO Year
- CPTN N/A
- SCYX 2014
- Fundamental
- Price
- CPTN $3.20
- SCYX $1.00
- Analyst Decision
- CPTN Hold
- SCYX Buy
- Analyst Count
- CPTN 2
- SCYX 1
- Target Price
- CPTN $2.50
- SCYX N/A
- AVG Volume (30 Days)
- CPTN 73.7K
- SCYX 174.1K
- Earning Date
- CPTN 11-07-2024
- SCYX 11-06-2024
- Dividend Yield
- CPTN N/A
- SCYX N/A
- EPS Growth
- CPTN N/A
- SCYX N/A
- EPS
- CPTN N/A
- SCYX N/A
- Revenue
- CPTN $17,872,000.00
- SCYX $8,566,000.00
- Revenue This Year
- CPTN $43.75
- SCYX N/A
- Revenue Next Year
- CPTN $41.30
- SCYX $405.82
- P/E Ratio
- CPTN N/A
- SCYX N/A
- Revenue Growth
- CPTN 84.59
- SCYX N/A
- 52 Week Low
- CPTN $2.38
- SCYX $1.06
- 52 Week High
- CPTN $3.81
- SCYX $3.07
- Technical
- Relative Strength Index (RSI)
- CPTN 61.66
- SCYX 37.92
- Support Level
- CPTN $3.10
- SCYX $1.06
- Resistance Level
- CPTN $3.22
- SCYX $1.25
- Average True Range (ATR)
- CPTN 0.03
- SCYX 0.07
- MACD
- CPTN 0.00
- SCYX -0.01
- Stochastic Oscillator
- CPTN 65.27
- SCYX 17.65
About CPTN Cepton Inc.
Cepton Inc provides lidar-based solutions for a range of markets such as automotive, smart cities, smart spaces and smart industrial applications. The company's patented MMT-based lidar technology enables reliable, scalable and cost-effective solutions that deliver long range, high resolution 3D perception for smart applications.
About SCYX SCYNEXIS Inc.
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against a broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.